Comparing the top-performing healthcare funds by expense ratio, GLP-1 drug exposure, and UnitedHealth concentration risk.
10 Picks AnalyzedUpdated June 2026Expert Reviewed
For informational purposes only. This content does not constitute financial, investment, or legal advice. Always consult with a qualified professional before making investment decisions.
Choosing the best healthcare ETFs in 2026 requires a balanced understanding of defensive stability versus high-growth innovation. As capital rotates away from overextended tech valuations, healthcare has emerged as a primary beneficiary due to its attractive price-to-earnings ratios and the massive tailwind of GLP-1 weight-loss therapeutics. Investors must decide between core large-cap anchors that track the healthcare stocks in the S&P 500 index and more volatile, high-reward baskets found in the complete list of biotechnology companies listed on U.S. exchanges.
While the sector is traditionally considered “defensive,” 2026 has introduced specific regional and regulatory risks, particularly within the managed-care insurance space. For those seeking aggressive growth, leveraged options like the ★ LABU Stock Profile offer exposure to clinical breakthroughs, including developments within the list of small cap cancer stocks. This guide provides a tiered framework to help you select the right fund based on your risk tolerance and interest in the current AI-driven diagnostics and drug-discovery cycle.
Strategic Summary
Best Healthcare ETFs — 2026 Market Insights
01The GLP-1 Tailwind
Pharmaceutical-heavy ETFs have significantly outperformed service-provider funds in 2026, driven by Eli Lilly and Novo Nordisk’s weight-loss drug dominance.
02Managed Care Pressure
Insurers like UnitedHealth (UNH) face regulatory headwinds and rising medical loss ratios, making insurance-specific ETFs (IHF) more volatile than broad sector funds.
03Broad vs. Concentrated
Funds like VHT provide 400+ holdings for total diversification, while XLV focuses on the top 60-70 mega-caps, leading to higher single-stock concentration risk.
04Biotech Structuring
Equal-weighted funds (XBI) are outperforming market-cap-weighted biotech (IBB) in 2026 as M&A activity targets small-cap innovators rather than established giants.
ETF Benchmarking
Top 10 Healthcare ETFs Compared
ETF Name
Ticker
Expense
Div Yield
1Y Return
5Y Return
Best For
Health Care Select Sector SPDR
XLV
0.08%
1.50%
11.67%
7.50%
Core Portfolio Large-Cap
Vanguard Healthcare ETF
VHT
0.09%
1.43%
16.75%
7.49%
Total Sector Coverage
iShares U.S. Medical Devices
IHI
0.40%
0.55%
14.10%
6.20%
Surgical Robotics & Hardware
SPDR S&P Biotech ETF
XBI
0.35%
0.20%
22.40%
-1.10%
High-Upside Small-Cap Biotech
iShares Biotechnology ETF
IBB
0.45%
0.38%
12.80%
3.90%
Mega-Cap Biotech Stability
iShares U.S. Healthcare ETF
IYH
0.40%
1.17%
11.50%
7.40%
Liquid Alternative Indexing
Fidelity MSCI Health Care
FHLC
0.08%
1.45%
16.50%
7.35%
Retail Buy-and-Hold
iShares Global Healthcare
IXJ
0.40%
1.44%
4.38%
5.41%
International Drug Makers
Invesco S&P 500 Equal Weight Health
RSPH
0.40%
1.10%
8.90%
5.15%
Mitigating Concentration Risk
iShares U.S. Healthcare Providers
IHF
0.40%
1.05%
-4.20%
6.80%
Insurance & Managed Care
Our Top Choice
Our Top Pick: Health Care Select Sector SPDR (XLV)
★Why It Tops Our List
XLV offers institutional-grade liquidity and the lowest expense ratio in the category. It captures the highly profitable, cash-flow-rich leaders of the S&P 500 healthcare sector.
📊Key Stats
Holds ~$40B in assets with a healthy 1.50% dividend yield. Top holdings include Eli Lilly, UnitedHealth, and Johnson & Johnson.
🎯Best For
Conservative investors seeking a defensive anchor that provides both capital appreciation and growing dividend income.
⚠️One Drawback
High concentration in the top 10 holdings (over 50% of the fund), making it sensitive to single-stock volatility like UNH or LLY price swings.
Detailed Analysis
Top Healthcare ETF Reviews
Health Care Select Sector SPDR
XLV
Expense: 0.08% | Yield: 1.50%
XLV remains the industry standard for healthcare investing. By tracking the S&P 500 Health Care Index, it effectively filters for the highest-quality, most established businesses in the sector. In 2026, its heavy weighting in Eli Lilly has allowed it to capture the obesity-drug boom, while its inclusion of medical stalwarts like JNJ provides a defensive floor. It is ultra-liquid, making it suitable for both long-term holders and tactical swing traders who want the tightest bid-ask spreads.
Vanguard Healthcare ETF
VHT
Expense: 0.09% | Yield: 1.43%
VHT is our preferred “broad-spectrum” fund. Unlike XLV, which only looks at the S&P 500, VHT holds over 400 stocks including many small- and mid-cap companies that are often targets for acquisition by larger pharmaceutical giants. This broader exposure has led to a slight outperformance over XLV during 2025-2026 as biotech and medical device small-caps rebounded. For a 0.09% fee, it provides nearly identical mega-cap exposure to XLV but adds a “kicker” of high-growth smaller firms.
iShares U.S. Medical Devices ETF
IHI
Expense: 0.40% | Yield: 0.55%
IHI focuses on the technical side of medicine—hardware, robotics, and surgical tools. It is anchored by Intuitive Surgical (ISRG) and Thermo Fisher (TMO). This fund is less sensitive to drug-pricing legislation and more tied to hospital capital expenditure and the volume of elective surgeries. In 2026, with the integration of AI-assisted surgery, IHI has seen strong momentum, though its higher 0.40% expense ratio makes it a more tactical “satellite” play than a core holding.
SPDR S&P Biotech ETF
XBI
Expense: 0.35% | Yield: 0.20%
XBI is structurally unique because it is equal-weighted. This means it gives as much influence to a $500M clinical-stage biotech as it does to a multi-billion dollar giant. This structure makes XBI the ultimate play on a biotech M&A cycle. If you believe clinical trial successes in small-cap oncology or rare disease will drive the sector, XBI is the tool of choice. It is significantly more volatile than broad funds and carries no meaningful dividend.
iShares Biotechnology ETF
IBB
Expense: 0.45% | Yield: 0.38%
IBB is the market-cap-weighted counterpart to XBI. It is dominated by massive, cash-flow-positive biotech firms like Amgen and Gilead. This fund offers a “tame” version of biotech growth, reducing the risk of single-trial failure blowups that can plague equal-weighted funds. In 2026, IBB has underperformed XBI as the market favored smaller innovators, but it remains a safer way to gain exposure to the drug-discovery lifecycle without extreme small-cap risk.
Fidelity MSCI Health Care Index ETF
FHLC
Expense: 0.08% | Yield: 1.45%
FHLC is Fidelity’s answer to XLV and VHT. It is the cheapest fund in the list, tied with XLV at 0.08%. Its index methodology is very similar to VHT, providing broad exposure across all market caps. For retail investors on the Fidelity platform, FHLC is often the best choice for a tax-efficient, low-turnover core healthcare holding. It captures the full breadth of the U.S. healthcare system from drug retail to clinical diagnostics.
iShares Global Healthcare ETF
IXJ
Expense: 0.40% | Yield: 1.44%
IXJ provides essential international diversification. While U.S. funds are dominant, IXJ includes major European and Japanese players like AstraZeneca, Novartis, and Takeda. In a year where U.S. drug-pricing regulation is a major political talking point, IXJ provides a hedge through its exposure to different regulatory jurisdictions. It remains a “buy-and-hold” favorite for globalists looking to capture the total worldwide healthcare spending trend.
Invesco S&P 500 Equal Weight Health Care
RSPH
Expense: 0.40% | Yield: 1.10%
RSPH is the solution for investors worried about the valuation of Eli Lilly and UnitedHealth. By giving every stock in the S&P 500 healthcare sector a 1.5% to 2% weighting, it prevents any single stock from dictating the fund’s performance. In mid-2026, with Eli Lilly trading at over 80x earnings, RSPH has seen increased inflows from value-conscious investors looking to stay in healthcare while reducing their exposure to the GLP-1 “hype” valuation.
Buyer’s Guide
How to Choose the Best Healthcare ETF
The healthcare landscape of 2026 is split between two massive themes: the “Pills” (Pharma/Biotech) and the “Providers” (Managed Care/Hospitals). Your choice of ETF determines which of these trends you are betting on.
The UnitedHealth (UNH) Factor
UnitedHealth is the massive “elephant” in almost every broad healthcare ETF. As of June 2026, UNH accounts for roughly 10-12% of XLV. If you believe the insurance sector is over-regulated or facing rising costs, you should look toward equal-weighted funds (RSPH) or pure biotech funds (XBI) to dilute this specific exposure.
GLP-1 and Pharma Innovation
For exposure to the obesity and diabetes drug market, focus on funds with heavy Eli Lilly (LLY) and AbbVie (ABBV) weightings. Funds like XLV and IYH are currently dominated by these pharmaceutical leaders. Conversely, if you want to avoid the “high-valuation pharma” trade, medical device funds like IHI provide a more hardware-centric alternative.
Investor Awareness
What to Avoid in Healthcare Investing
Managed Care Concentration
Avoid funds like IHF unless you have a high conviction in the insurance industry. Managed care is currently facing significant margin compression due to rising medical costs and government reimbursement cuts.
Clinical Trial Binary Risk
Biotech ETFs, especially equal-weighted ones, are subject to “binary events”—success or failure of drug trials that can cause 20% swings in a single day. Only allocate capital you can afford to lose.
Regulatory Overhang
Drug-pricing legislation (like the Inflation Reduction Act’s negotiation clauses) poses a long-term threat to pharmaceutical margins. Ensure your ETF includes non-pharma stocks for balance.
High Turnover Fees
Avoid thematic healthcare ETFs with expense ratios above 0.75%. In a defensive sector, high fees can quickly eat away at the moderate 7-9% annual returns typical of the industry.
Common Questions
Frequently Asked Questions
XLV is best for conservative investors wanting low-cost mega-cap stability within the S&P 500. VHT is better for those who want total sector exposure, including smaller, high-growth companies that are excluded from the S&P 500.
XLV typically holds 10-12% in UNH, while VHT holds about 8%. If you buy IHF, your exposure jumps to over 20%, making it highly sensitive to the insurance sector’s health.
Yes, they are much higher risk than broad funds. They should usually be a satellite position (5-10% of portfolio) rather than a core holding due to high volatility and lack of dividends.
XLV and IYH have the highest concentration in Eli Lilly. For global exposure to Novo Nordisk, the IXJ ETF is the better choice.
It remains defensive because demand for healthcare is inelastic, but high valuations in pharma and regulatory risks in insurance have made it slightly more volatile than in previous decades.
XLV tracks S&P 500 stocks only, while IYH tracks the broader Russell 1000 index. IYH includes slightly more mid-cap exposure but carries a much higher expense ratio of 0.40% vs XLV’s 0.08%.
Broad funds like XLV and VHT pay moderate yields around 1.4-1.5%. Specialized biotech funds typically pay very little (0.2%), while medical device funds are also low (0.5%).
Legislation that limits drug prices can compress profit margins for pharma giants. ETFs that are diversified into medical devices and healthcare services (VHT) are better insulated from this risk.
XBI is equal-weighted and tilts heavily toward small-cap biotech innovators. IBB is market-cap-weighted and tilts toward established mega-cap firms with proven drug revenues.
Many analysts believe the rotation still has legs as tech remains expensive. Healthcare provides a “valuation catch-up” opportunity while offering a safety net if the economy slows in 2026.
Continue Research
Related Healthcare Resources
Leveraged ETF
LABU Stock Profile
Understanding the high risks of 3x daily leveraged exposure to the S&P Biotech Select Industry Index.
Last updated June 2026 · Data sourced from fund prospectuses and institutional filings.
Focus Keyword: Best Healthcare ETFs
Meta Title: 10 Best Healthcare ETFs to Buy in 2026 | Analysis
Meta Description: Compare top healthcare ETFs for 2026. See XLV vs VHT data, GLP-1 drug exposure levels, and the best biotech funds for your medical sector portfolio.
Page URL: https://investsnips.com/best-healthcare-etfs/
